Drug interactions
Mavacamten + Pioglitazone
Severity: Minor
Mavacamten and Pioglitazone: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Mavacamten is metabolized substantially by CYP2C19, with contributions from CYP3A4. Pioglitazone is not an established clinically meaningful CYP2C19 inhibitor, so the predicted rise in mavacamten exposure is uncertain. If exposure did rise, excessive reduction in ejection fraction and heart failure could occur.
What this interaction means in plain words
Mavacamten and Pioglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Mavacamten belongs to Cardiovascular; Pioglitazone belongs to Endocrine.
Why it happens
Possible weak inhibition of CYP2C19 metabolism of mavacamten, which is not well established for pioglitazone.
What to do
No empirical dose change is needed, but follow the routine echocardiographic LVEF monitoring required for mavacamten. Reassess LVEF if clinical status changes after pioglitazone is started or stopped.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Mavacamten and Pioglitazone, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Pioglitazone
Other interactions of Mavacamten
- Apalutamide + Mavacamten Contraindicated
- Carbamazepine + Mavacamten Contraindicated
- Clarithromycin + Mavacamten Contraindicated
- Dexlansoprazole + Mavacamten Contraindicated
- Efavirenz + Mavacamten Contraindicated
- Enzalutamide + Mavacamten Contraindicated
Frequently asked questions
Can I take Mavacamten with Pioglitazone?
MediHelp rates the interaction as minor. Mavacamten and Pioglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Mavacamten is metabolized substantially by CYP2C19, with contributions from CYP3A4. Pioglitazone is not an established clinically meaningful CYP2C19 inhibitor, so the predicted rise in mavacamten exposure is uncertain. If exposure did rise, excessive reduction in ejection fraction and heart failure could occur.
How serious is the interaction between Mavacamten and Pioglitazone?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empirical dose change is needed, but follow the routine echocardiographic LVEF monitoring required for mavacamten. Reassess LVEF if clinical status changes after pioglitazone is started or stopped.
What other medicines interact with Pioglitazone?
MediHelp also lists interactions of Pioglitazone with, for example, Insulin aspart-insulin aspart protamine, Insulin aspart, Insulin degludec-insulin aspart. The full list is on the Pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
